ClinicalTrials.gg
RecruitingNCT07363460Updated Jan 23, 2026

Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN

A Phase 2 interventional study of HSK39297 200mgQD and HSK39297 300mgQD in Lupus Nephritis (LN), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 96 studies in Lupus Nephritis with a site in China — 43 open to participants now, 46 under way, 8 of them phase 3. Lupus Nephritis · China.

Planned enrollment
27th of 88
105 · median 51
Started
2025
with 18 others
Phase 2
19 of 96
8 open now
Primary completion
2027-11
later than 31 of 45 live
Registered
85th of 96
by date

Among the 96 studies in Lupus Nephritis with a site in China, this one is the 27th largest by planned enrollment of the 88 interventional ones that give a count, is one of 19 that started in 2025, is one of 19 in phase 2, reaches primary completion later than 31 of the 45 other live ones, and was the 85th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

43 of the 96 studies in Lupus Nephritis with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Lupus Nephritis with a site in China, or all of them as a file.
02

Study summary

A double-blind,placebo controlled,randomized Phase 2 study to evaluate the safety and tolerability of once-daily, oral administration of 200 or 300 mg HSK39297 tablets versus placebo in Patients With Lupus Nephritis

03

Conditions studied

  • Lupus Nephritis (LN)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand and comply with the research requirements, voluntarily participate in the research and sign the form before starting the relevant procedures;
  2. Age ≥ 18 and \< 75 years old at screening, gender not limited;
  3. Positive anti-ANA antibody and/or anti-dsDNA antibody (research center);
  4. Pathological type of active III or IV lupus nephritis confirmed by renal within 12 months before screening, with or without type V (adopting the 2003 International Society of Nephrology/Renal Pathology Working Group's lupus nephritis pathological classification criteria, see Appendix 2; for recurrent subjects, the investigator assesses whether a repeat renal biopsy is necessary; renal biopsy is conducted after confirming that the subject meets all other inclusion criterias and does not meet the exclusion criterias);
  5. Evidence of active lupus nephritis exists, and the investigator assesses that it is necessary to receive combined with MMF treatment. Active lupus nephritis must meet the following two criterias:

    a) Proteinuria:

    a) At screening: 24h-UPCR ≥ 1g/g or FMV-UPCR ≥ 1g/g or FMV-UACR ≥ 0.5g/g; b) Before randomization: 24h-UPCR ≥ 1g/g (central laboratory); b) At screening: SLEDAI-2000 ≥ 8;

  6. First onset or recurrence of lupus nephritis (for subjects who have received MMF treatment previously and have experienced recurrence, the investigator and the sponsor jointly assess the benefit based on the study's medication regimen to determine whether they can be enrolled);
  7. Female subjects with reproductive capacity [excluding those who have undergone surgical sterilization (hysterectomy, bilateral tubal ligation, bilateral oophorectomy) at least 6 weeks prior to screening or who are (defined as having no menstruation for 12 months, with no other medical cause)]; a negative pregnancy test must be confirmed during the screening period. The subject must agree not to attempt pregnancy and not to donate oocytes from the date of signing the informed consent form until at least 30 days after the last administration of product, and must use effective ; male subjects must agree not to donate sperm for at least 90 days from the date of signing the informed consent form until at least 90 days after the last administration of investigational product, and must use highly effective contraception with their female partners (see Appendix 3).

Exclusion criteria

Exclusion Criteria:

  1. The subject has previously failed to respond to treatment with MMF or other mofetil mycophenolate drugs, as assessed by the investigator.
  2. Allergy to the product or MMF, or to MMF and .
  3. Currently receiving or requiring administration of any drug listed in Section 5.7.2.2 "Prohibited Concomitant Medications" during the study period.
  4. Receiving systemic glucocorticoid therapy for reasons other than systemic lupus erythematosus or lupus nephritis at screening (dose > 10 mg/day prednisone or equivalent; dosage conversion details see Appendix 4).
  5. Received treatment with other investigational drugs within 30 days prior to screening or within 5 half-lives (whichever is longer).
  6. Presence of rapidly progressive glomerulonephritis at screening ( decline exceeding 50% within 3 months, or less than 50% but with rapid decline risk assessed by the investigator); renal showing crescents occupying more than 50% of glomeruli, or glomerulosclerosis exceeding 60%, or tubular atrophy/interstitial fibrosis exceeding 60%.
  7. Presence of severe extra-renal manifestations of systemic lupus erythematosus at screening, including but not limited to severe pulmonary hypertension (WHO classification IV or higher), severe pulmonary interstitial fibrosis, severe myocarditis, severe heart failure ( classification IV), or active central nervous system lupus.
  8. Major, unstable, or uncontrolled acute or chronic diseases affecting various systems (e.g., cardiovascular, respiratory, hematological, gastrointestinal, hepatic, renal, neurological systems) within 6 months prior to screening or at screening that may affect study results or place the subject at high risk, excluding those caused by SLE.
  9. History of other diseases.
  10. History of any of the following infections:

1) History of encapsulated bacterial infection (e.g., Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae) within 1 year prior to screening; 2) Active tuberculosis at screening; history of active tuberculosis within 2 years prior to screening; history of active tuberculosis currently cured but assessed by the investigator to be at risk for reactivation; positive interferon-gamma release assay with determination by the investigator or consulting specialist physician that it represents latent tuberculosis requiring prophylactic anti-tuberculosis treatment; 3) History of other active infections requiring antimicrobial treatment within 3 months prior to screening.

11. History of major organ (heart, lung, kidney, liver) transplantation or hematopoietic stem cell/bone marrow transplantation, or planned for transplantation.

12. Currently undergoing regular hemodialysis or planning to undergo hemodialysis during the study period.

13. History of gastrointestinal surgery that may significantly affect drug absorption, distribution, metabolism, and excretion, or history of severe gastrointestinal disease, or difficulty in swallowing, frequent vomiting leading to difficulty in eating or taking medication.

14. Diagnosis of within 5 years prior to screening, excluding basal cell carcinoma of the skin, papillary thyroid carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ.

15. Major surgical procedures within 6 months prior to screening. 16. Laboratory tests at screening meet any of the following criteria:

  1. Estimated Glomerular Filtration Rate (eGFR) \< 30 ml/min/1.73m² (calculated by CKD-EPI 2021 formula, see Appendix 5);
  2. Hematology: neutrophils \< 1 × 10⁹/L; leukocytes \< 2 × 10⁹/L; \< 80 g/L; \< 50 × 10⁹/L;
  3. Liver function: (ALT) or Aspartate Aminotransferase (AST) ≥ 3 × ; Total (TBIL) ≥ 2 × ULN;
  4. virus surface antigen (HBsAg) positive, or HBsAg negative but Hepatitis B virus core antibody (HBc-Ab) positive with HBV-DNA detection result higher than the quantitative lower limit; virus antibody (HCV-Ab) positive;
  5. antibody (HIV-Ab) positive. 17. Pregnant or lactating female subjects at screening. 18. Other situations deemed unsuitable for participation by the investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
105 participants (estimated)

Study arms

  • Active comparator
    200mg QD

    Patients take double-blind HSK39297 tablets 200mg for 52 weeks

    Drug: HSK39297 200mgQD

  • Active comparator
    300mg QD

    Patients take double-blind HSK39297 tablets 300mg for 52 weeks

    Drug: HSK39297 300mgQD

  • Placebo comparator
    Placebo

    Patients take double-blind placebo for 52 weeks

    Drug: Placebo

Interventions

  • once daily, oral administration of HSK39297 tablets 200mg from Day 1 to Week 52.

  • once daily, oral administration of HSK39297 tablets 300mg from Day 1 to Week 52.

  • DrugPlacebo

    once daily, oral administration of placebo from Day 1 to Week 52.

06

What researchers measure

Primary outcomes

  1. Ratio of 24h-UPCR compared to Baseline

    Urine Protein Creatinine Ratio

    Time frame: 24 weeks

Secondary outcomes

  1. Proportion achieving CRR/PRR

    Complete Renal Response,Partial Renal Response

    Time frame: 12,24,52 weeks

  2. Proportion achieving CRR/PRR without renal recurrence

    Complete Renal Response,Partial Renal Response

    Time frame: 24,52 weeks

  3. Proportion achieving CRR/PRR with glucocorticoid ≤ 5mg/d

    Complete Renal Response,Partial Renal Response

    Time frame: 24,52weeks

  4. Proportion achieving 25%/50% reduction in 24h-UPCR

    Urine Protein Creatinine Ratio

    Time frame: 12,24,52 weeks

  5. Time to first achievement of CRR, 25%/50% proteinuria reduction

    Complete Renal Response

    Time frame: from baseline to 52 weeks

  6. Duration of sustained CRR/PRR

    Complete Renal Response,Partial Renal Response

    Time frame: from baseline to 52 weeks

  7. Change in 24h-UPCR from baseline.

    Urine Protein Creatinine Ratio

    Time frame: from baseline to 52 weeks

  8. Change in eGFR from baseline

    Estimated glomerular filtration rate

    Time frame: 12,24,52 weeks

  9. Proportion with Glucocorticoid dose ≤ 5mg/d

    Time frame: 24,52 weeks

  10. Annualized slope of eGFR

    Estimated glomerular filtration rate

    Time frame: 52 weeks

  11. Change in SLEDAI-2000 (Systemic lupus erythematosus disease activity index 2000,SLEDAI-2000)total score from baseline

    SLEDAI-2000 scale ranges form 0 to 105 score. The higher scores indicate a higher disease activity level of the subject's systemic lupus erythematosus .

    Time frame: 12, 24, 52 weeks

  12. Incidence and severity of adverse events (AEs)

    Time frame: 52 weeks

  13. Pharmacokinetic characteristics(Cmax) of HSK39297 tablets in plasma.

    Time frame: 52 weeks

  14. Pharmacokinetic characteristics(Cmin) of HSK39297 tablets in plasma.

    Time frame: 52 weeks

  15. Pharmacokinetic characteristics(Cavg) of HSK39297 tablets in plasma.

    Time frame: 52 weeks

  16. Pharmacokinetic characteristics(Tmax) of HSK39297 tablets in plasma.

    Time frame: 52 weeks

  17. Pharmacokinetic characteristics(AUC0-τ) of HSK39297 tablets in plasma.

    Time frame: 52 weeks

  18. Changes from baseline of pharmacodynamic indicators(Ap)

    Time frame: 52 weeks

  19. Changes from baseline of pharmacodynamic indicators(Bb)

    Time frame: 52 weeks

  20. Changes from baseline of pharmacodynamic indicators(sC5b-9)

    Time frame: 52 weeks

  21. Changes from baseline in biological markers (C3)reflecting immunological activity of lupus nephritis

    Time frame: 52 weeks

  22. Changes from baseline in biological markers (C4)reflecting immunological activity of lupus nephritis

    Time frame: 52 weeks

  23. Changes from baseline in biological markers (anti-dsDNA antibody)reflecting immunological activity of lupus nephritis

    Time frame: 52 weeks

  24. Change in FACIT-F (Functional Assessment of Chronic Illness Therapy-Fatigue)score from baseline

    FACIT-F scale ranges from 0 to 52 score,and the higher scores indicate a better condition of the subject and less fatigue.

    Time frame: 52 weeks

07

Study locations

1 of 1 sites recruiting
  • Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine
    Nanjing, Jiangsu 210000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 23 months after the start.

Of 33 phase 2 interventional studies under Lupus Nephritis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2025
First posted
Jan 23, 2026
StartActual
Nov 18, 2025
Primary completionEst.
Nov 5, 2027
CompletionEst.
Jul 6, 2028
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07363460
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Nov 18, 2025
Primary completion
Nov 5, 2027 (estimated)
Completion
Jul 6, 2028 (estimated)
Last update
Jan 23, 2026

Study contacts

fangqiong Li
Contact
lifangq@haisco.com
+86028-67258840
bicheng Liu
principal investigator · Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK39297

Start the discussion